3rd Quarter - Report — STEPTOE LLP for OREXO US, INC. (2026)

Firm

STEPTOE LLP

Client

OREXO US, INC.

Income

$100,000

Expenses

—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Alcohol and Drug Abuse ALC

Advocacy on xylazine and adultered-opioid overdose solutions and federal funding.

Foreign entity interest: Orexo US, Inc. is a subsidiary of Orexo AB. Orexo AB, based in Sweden and identified on Registration (LD-1), has an interest in policies related to pharmaceuticals.

Lobbyist	Covered position, as disclosed
LESLIE BELCHER	—
ROWAN BOST	—
TAYLOR BUSH	—
MATTHEW FLYNN	—

Contacted: White House Office; Justice, Dept of (DOJ); Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA)

Budget/Appropriations BUD

Advocacy on xylazine and adultered-opioid overdose solutions and federal funding.

Foreign entity interest: Orexo US, Inc. is a subsidiary of Orexo AB. Orexo AB, based in Sweden and identified on Registration (LD-1), has an interest in policies related to pharmaceuticals.

Lobbyist	Covered position, as disclosed
LESLIE BELCHER	—
ROWAN BOST	—
TAYLOR BUSH	—
MATTHEW FLYNN	—

Contacted: Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); Justice, Dept of (DOJ); White House Office; Food & Drug Administration (FDA)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.